In a recent statement to the Vaccine Safety Research Foundation, Dr. Geert Vanden Bossche responded to Steve Kirsch and estimated that around 30% to 40% of the highly vaccinated population will be wiped out.
Dear all, It’s impossible to convey the intricacies of my analysis through e-mail, but I must emphasize the impending emergence of yet another, but spectacularly different SARS-CoV-2 (SC-2) variant that I strongly predict to cause highly virulent vaccine breakthrough infections (VBTIs) in highly COVID-19 (C-19) vaccinated populations.
This conclusion can be drawn from the notable rise in the prevalence of JN.1, which has incorporated several replication-enhancing mutations beyond the spike (S) protein, combined with the concomitant increase in the C-19 hospitalization and mortality rates, as currently observed in the USA and several European countries.
Painfully, several scientists and so-called ‘experts’ persist in the belief that currently circulating variants, including JN.1, remain neutralized after vaccination with updated booster vaccines (e.g., with the XBB.1.5 vaccine). However, they don’t grasp that updated booster vaccines only confer a short-lived neutralization activity to the crossvariant S-reactive Abs previously induced as a result of immune refocusing following vaccine breakthrough infections (VBTIs) with newly emerging variants. This short-lived neutralization effect rapidly transitions into a more stable suboptimal infection-inhibiting (i.e., infection-mitigating) effect. The latter causes highly C-19 vaccinated populations to collectively exert immune selection pressure on viral infectiousness and, therefore, drives the propagation of more infectious variants!
These newly emerging, more infectious variants don’t leave enough time to the immune system of C-19 vaccines to sustain the production of non-neutralizing Abs (NNAbs), the production of which used to be triggered by the interaction of previously induced neutralizing Abs that exhibit a strongly diminished neutralizing capacity towards the new infecting S variant.
NNAbs have repeatedly been reported to facilitate VBTIs with newly emerging SC-2 variants by virtue of their infection-enhancing effect. As the concentration of these NNAbs produced upon VBTIs in highly C-19 vaccinated populations will soon collectively decrease to suboptimal levels, SC-2 is poised to undergo a spectacular mutation to overcome the immune selection pressure collectively exerted by these Abs on the virus’s capacity to prevent their virulence-inhibiting activity. This implies that high infection rates in highly C-19 vaccinated populations will no longer benefit from a protective effect against severe C-19 disease.
The unexpected emergence of Omicron and its significant mutational changes in the receptor-binding domain of S protein (S-RBD) has caught us all off guard. The advent of Omicron was a scourge as it paved the way for the imminent appearance of a new variant, only expected to emerge much more suddenly and come with mutations (presumably in the O-glycosylation profile) that are even much more spectacular. Unlike the previous situation with the advent of Omicron, the consequence this time will not be limited to heightened infectiousness but will be compounded by a high level of viral virulence. As I repeated over and over again: “Society in highly C-19 vaccinated countries will be caught off guard”.
Unvaccinated individuals, though, have long since transitioned from adaptive humoral adaptive immunity to trained cell-based innate immunity to cope with the variants. Therefore, the feared variant poses no problem for a non-vaccinated individual in good health. That’s why I keep saying that ‘Africa will win’.
I am describing the above-summarized insidious immune subversive mechanisms in more detail in a new article; however, it may not be finished before the tsunami hits… What else can I do at this point other than to cite Sherlock Holmes: “How often have I said to you that when you have eliminated the impossible, whatever remains, however improbable, must be the truth?”
